Erratum: Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial (The Lancet (2016) 388(10040) (158–169) (S0140673616007030) (10.1016/S0140-6736(16)00703-0));Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial

The Lancet

Volumn 388, Issue 10040, 2016, Pages 158-169

  Asturias, Edwin J ^a,b,c   Bandyopadhyay, Ananda S ^d   Self, Steve ^e   Rivera, Luis ^f   Saez Llorens, Xavier ^g   Lopez, Eduardo ^h   Melgar, Mario ⁱ   Gaensbauer, James T ^a,b,c   Weldon, William C ^j   Oberste, M Steven ^j   Borate, Bhavesh R ^e   Gast, Chris ^e   Clemens, Ralf ⁿ   Orenstein, Walter ^k   O'Ryan G, Miguel ^l   Jimeno, José ^m   Clemens, Sue Ann Costa ⁿ   Ward, Joel ^o   Rüttimann, Ricardo ^p  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c Food Science and Human Nutrition   (United States)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

^e USA   (United States)

^f Center for Neonatal Research   (Dominican Republic)

^g Hospital del Nino Dr Jose Renan Esquivel ^*  (Panama)

^h UNIVERSIDAD DEL VALLE   (Colombia)

ⁱ Universidad Francisco Marroquin   (Guatemala)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^k EMORY UNIVERSITY   (United States)

^l UNIVERSITY OF CHILE   (Chile)

^m Vaxtrials   (Panama)

ⁿ Global Research in Infectious Diseases   (Brazil)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p Fighting Infectious Diseases in Emerging Countries (FIDEC)   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; COLOMBIA; CONTROLLED STUDY; DOMINICAN REPUBLIC; FEMALE; GUATEMALA; HUMAN; HUMORAL IMMUNITY; IMMUNITY; IMMUNOGENICITY; INFANT; INTESTINAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PANAMA; PHYSICAL EXAMINATION; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROTYPE; SINGLE BLIND PROCEDURE; VACCINATION; VIRUS SHEDDING; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; FECES; IMMUNIZATION; IMMUNOLOGY; INTESTINE MUCOSA; MUCOSAL IMMUNITY; SOUTH AND CENTRAL AMERICA; VIROLOGY;

ANTIBODIES, NEUTRALIZING; COLOMBIA; DOMINICAN REPUBLIC; DRUG THERAPY, COMBINATION; FECES; FEMALE; GUATEMALA; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; INFANT; INTESTINAL MUCOSA; LATIN AMERICA; MALE; PANAMA; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; SEROCONVERSION; SINGLE-BLIND METHOD; VIRUS SHEDDING;

EID: 84969580025     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30981-3     Document Type: Erratum

References (21)

1. 1 Global Polio Eradication Initiative. Polio this week as of 9 December 2015. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx (accessed Dec 12, 2015).
2. 2 Bandyopadhyay, AS, Garon, J, Seib, K, Orenstein, WA, Polio vaccination: past, present and future. Future Microbiol 10 (2015), 791–808.
3. 3 Platt, LR, Estivariz, CF, Sutter, RW, Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 210:suppl 1 (2014), S380–S389.
4. 4 WHO. Polio vaccines: WHO position paper, January 2014—recommendations. Vaccine 32 (2014), 4117–4118.
5. 5 Polio Eradication and Endgame Strategic Plan 2013–2018. http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_ES_EN_A4.pdf (accessed Dec 12, 2015).
6. 6 Plotkin, SA, Correlates of vaccine-induced immunity. Clin Infect Dis 47 (2008), 401–409.
7. 7 O'Ryan, M, Bandyopadhyay, AS, Villena, R, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis 15 (2015), 1273–1282.
8. 8 Sáez-Llorens, X, Clemens, R, Leroux-Roels, G, et al. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis 16 (2016), 321–330.
9. 9 Patriarca, PA, Wright, PF, John, TJ, Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 13 (1991), 926–939.
10. 10 Sutter, RW, Bahl, S, Deshpande, JM, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet 386 (2015), 2413–2421.
11. 11 Estívariz, CF, Anand, A, Gary, HE Jr, et al. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis 15 (2015), 898–904.
12. 12 Mir, F, Quadri, F, Mach, O, et al. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial. Lancet Infect Dis 15 (2015), 889–897.
13. 13 Grassly, NC, Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis 210:suppl 1 (2014), S439–S446.
14. 14 Sabin, AB, Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus. J Exp Med 96 (1952), 99–106.
15. 15 Ashkenazi, A, Melnick, JL, Heterotypic antibody response after feeding on monovalent attenuated live poliovaccine. N Engl J Med 267 (1962), 1228–1230.
16. 16 Netea, MG, Quintin, J, van der Meer, JW, Trained immunity: a memory for innate host defense. Cell Host Microbe 9 (2011), 355–361.
17. 17 Hong, M, Sandalova, E, Low, D, et al. Trained immunity in newborn infants of HBV-infected mothers. Nat Commun, 6, 2015, 6588.
18. 18 Herremans, MMPT, Reimerink, JHJ, Buisman, AM, Kimman, TG, Koopmans, MPG, Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 162 (1999), 5011–5018.
19. 19 John, J, Giri, S, Karthikeyan, AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 384 (2014), 1505–1512.
20. 20 Jafari, H, Deshpande, JM, Sutter, RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 345 (2014), 922–925.
21. 21 de Quadros, CA, Henderson, DA, Disease eradication and control in the Americas. Biologicals 21 (1993), 335–343.